The FDA has approved capmatinib [24] and tepotinib [22], highly selective and potent oral MET inhibitors for MET∆ex14-amplified tumors that have demonstrated significant clinical benefits in both treatment-naïve and previously treated patients with advanced, metastatic NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.